-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationAspirin
Sanofi axed two more cancer-preventing monoclonal antibodies in Phase 1 clinical trials, weeks after terminating a cell therapy partnership with Sangamo
The large French pharmaceutical company disclosed the axed items during its full-year 2021 earnings call on February 4, 2022
As Sanofi CEO Paul Hudson described in December 2019, the two drug candidates are part of Sanofi's push into the next cycle of its drug development, but the cuts could be nearly as bad for the company's pipeline.
SAR439459, an anti-TGFb therapy
Sanofi's trial entry for SAR442085 was updated on January 14 and listed the trial status as recruiting
The news comes just weeks after Sanofi said it would end its cell therapy agreement with Sangamo
Reference: Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo deal